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Abstract
Purpose: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple 
signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus 
(EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or 
persistent ovarian, fallopian tube or primary peritoneal cancer (OC).
Patients and Methods: Eligible OC patients had measurable (RECIST1.1) or detectable 
disease, 1–3 prior regimens, performance status (PS) 0–2, and no prior m-TOR inhibitor. All 
patients received BV 10 mg/kg IV every 2wks. Patients were randomized (1:1) to oral EV (10 mg 
daily) or placebo stratified by platinum-free interval (PFI), measurable disease and prior BV. 
Primary endpoint was progression-free survival (PFS); secondary endpoints included safety and 
response.
Results: 150 patients were randomized to BV with (n=75) and without (n=75) EV. Arms were 
well-balanced for age (median 63: range 28–92), PS (0: 73%, 1–2: 27%), prior regimens (1: 37%, 
2: 47%, 3: 16%), prior BV (11%), PFI (<6mos: 65%) and measurable disease (81%). The BV+EV 
vs BV median PFS was 5.9 vs 4.5 months (hazard ratio [HR] 0.95 (95% CI, 0.66–1.37, p=0.39)). 
Median OS was 16.6 vs 17.3 months (HR 1.16 (95% CI, 0.72~1.87, p=0.55). Objective 
measurable responses were higher with BV+EV (22% vs 12%). Study removal due to toxicity was 
higher with BV+EV (29% vs 12%). Toxicity (≥grade 3) from BV+EV were “other GI (mucositis)” 
(23 vs 1%) and “metabolic/nutrition” (19 vs. 7%); common >= grade 2 toxicities with BV+EV 
were cytopenia, nausea, fatigue and rash.
Conclusion: The combination regimen (BV+EV) did not significantly reduce the hazard of 
progression or death relative to BV and was associated with higher rates of adverse events and 
study discontinuation when compared to BV alone.
Keywords
Ovarian Cancer; Bevacizumab; Everolimus; Targeted Therapy
INTRODUCTION
Anti-vascular endothelial growth factor (VEGF) treatments have been shown to be an 
effective strategy for controlling tumor growth in ovarian cancer (OC) via the angiogenic 
and other growth pathways.1–3 Bevacizumab (BV), a recombinant humanized monoclonal 
antibody against VEGF, has clinical activity as both a single agent and in combination with 
cytotoxic chemtherapy.4–12 Based on improved progression-free survival (PFS) and overall 
survival (OS) in certain populations, bevacizumab is indicated in both platinum-resistant and 
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platium-sensitive recurrent ovarian cancer and in conjunction with platinum-based therapy in 
upfront treatment.
Everolimus, a rapalog-type inhibitor of mammalian target of rapamycin (mTOR) complex 1 
(mTORC1), attenuates up regulation of HIF-1α levels, a resistance mechanism for 
antiangiongenics, and targets the PI3-Kinase/AKT/mTOR axis, commonly abberant in OC.
13–16
 Everolimus (Afinitor, Novartis) has indications in advanced renal cell carcinoma 
(RCC), well-differentiated advanced neuroendocrine tumors (NET), advanced hormone 
receptor-positive, HER2-negative breast cancer in combination with exemestane, and renal 
angiomyolipoma and tuberous sclerosis complex.17
The Ovarian Carcinoma Cancer Genome Atlas Research Network identified PI3K/RAS 
pathway deregulation in 45% ovarian cases.18 Single agent rapalog trials in recurrent ovarian 
cancer have yielded modest results. The Gynecologic Oncology Group (GOG) performed a 
study of temsirolimus show ing a response rate (RR) of 9.3% (5/54 patients), with 24.1% of 
patients progression-free at 6 months.19 A similar study, performed by the AGO study group 
(AGO-GYN8) yielded a response rate of 4.5% (1/22 patients).20
Targreted therapy combinations that include blocking VEGF and other cancer growth 
pathways may circumvent resistance to angiogenesis inhibition and be more tolerable and 
effective compared to traditional cytotoxic combinations. Everolimus has been safely 
combined with bevacizumab and studied in a non-randomized phase 2 trial in advanced 
RCC.21–22 A phase 1 trial of bevacizumab and temsirolimus was performed in gynecologic 
malignancies showing safe delivery of full doses of both agents and a response rate of 17% 
(7/41 patients).23
The objective of this study was to assess PFS in a randomized phase II study of bevacizumab 
alone (with an oral placebo) versus the combination of bevacizumab and oral everolimus 
among women with recurrent epithelial ovarian cancer.
Patients and Methods:
The study was designed as a double-blind, placebo-controlled prospective randomized phase 
II trial of intravenous (IV) bevacizumab every 2 weeks in combination with either oral 
everolimus or an oral placebo (Gynecologic Oncology Group protocol 186-G; 
ClinicalTrials.gov. Identifier: NCT00886691).
Eligible patients included women older than 18 years of age with a GOG performance status 
of 0–2. All patients were required to have measurable (per RECIST 1.1) or detectable 
disease from persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal 
carcinoma. Detectable disease required at least one of the following conditions: baseline 
values of cancer antigen (CA)-125 at least 2 × upper-limit-of normal (ULN), ascites and/or 
pleural effusion attributed to tumor, or solid and/or cystic abnormalities on radiographic 
imaging that do not meet RECIST 1.1 definitions for target lesions. Patients must have had 
one prior platinum-based chemotherapeutic regimen for management of primary disease and 
were allowed to receive up to two additional cytotoxic regimens for management of 
recurrent or persistent disease, with no more than 1 non-platinum, non-taxane regimen. 
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Patients who have had one prior treatment must have had a GOG Performance Status of 0, 1, 
or 2; patients who have had two or three prior treatments must have had a GOG Performance 
Status of 0 or 1. Patients were allowed to receive biologic (non-cytotoxic) therapy, including 
VEGF blockade, as part of their primary treatment regimen, but not for recurrent or 
persistent disease. Patients with either platinum-sensitive (platinum-free interval (PFI) >182 
days) or platinum-resistant (PFI ≤182 days) disease were eligible. Patients who received 
only one prior cytotoxic regimen must have had a PFI ≤365 days or had progressed during 
platinum-based therapy, or had persistent disease after a platinum-based therapy.
Adequate laboratory studies included 1- bone marrow function defined as absolute 
neutrophil count (ANC) ≥1,500/mcl, platelets ≥100,000/mcl; 2- renal function defined as 
creatinine ≤1.5 × institutional ULN; 3- hepatic function defined as bilirubin ≤1.5 × ULN, 
SGOT (AST) ≤3 × ULN and alkaline phosphatase ≤2.5 × ULN; 4- blood coagulation 
parameters with PT such that international normalized ratio (INR) was ≤1.5 (or an in-range 
INR, usually between 2 and 3, if a patient was on a stable dose of therapeutic warfarin for 
management of deep vein thrombosis including pulmonary embolism) and a PTT ≤1.5 times 
the upper limit of normal; 5- fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND 
fasting triglycerides ≤300 mg/dL or 3.42 mmol/L; 6- Urine protein creatinine (UPC) ratio 
must have been <1.0 gm. If UPC ratio was ≥1, collection of 24-hour urine measurement of 
urine protein was recommended. UPC ratio of spot urine is an estimation of the 24-hour 
urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 
1 gm.
Patients were excluded if they had significant comorbifties including acute hepatitis, active 
infection requiring parenteral antibiotics, active bleeding (or bleeding disorder), CNS 
disease (including uncontrolled seizures, brain metastasis and history of cerebrovascular 
accident or bleed within six months of study treatment), cardiovascular disease (uncontrolled 
hypertension, defined as systolic >150 mm Hg or diastolic >90 mm Hg, myocardial 
infarction or unstable angina within six months prior to registration, New York Heart 
Association (NYHA) Class II or greater congestive heart failure, serious cardiac arrhythmia 
requiring medication, prior treatment with an anthracycline and had an ejection fraction 
<50%, or CTCAE Grade 2 or greater peripheral vascular disease), signs of gastrointestinal 
obstruction (including patients who require parenteral hydration and/or nutrition), serious 
wounds, abscess, or bowel perforation. Patients with prior recent invasive malignancies and 
those not recovered from the effects of recent surgery, radiotherapy, or chemotherapy were 
excluded. Patients of childbearing potential were required to have a negative serum 
pregnancy test before entering the study and were required to practice an effective form of 
contraception.
Any other prior therapy directed at the malignant tumor, including biological and 
immunologic agents, had to be discontinued at least three weeks prior to registration 
(including small molecules and murine monoclonal antibodies). Chimeric, human, or 
humanized monoclonal antibodies (including bevacizumab) or VEGF receptor fusion protein 
(including VEGF Trap, aflibercept) had to be discontinued for at least 12 weeks prior to 
registration. No investigational therapy within 30 days prior to the first date of study 
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treatment was allowed and patients who had received prior everolimus or any other mTOR 
inhibitor were excluded.
All patients signed an approved informed consent and authorization permitting the release of 
personal health information.
Blinding
Blinding was employed to help preserve the integrity of the PFS and OS endpoints by 
eliminating biases in disease assessment monitoring, the declaration of disease progression 
and the institution/selection of future therapies. Therefore, it was understood that 
investigators, patients and research personnel would not know if patients have received 
everolimus or placebo.
Drug Administration and Supportive Care
Bevacizumab was administered at 10 mg/kg as a continuous intravenous (IV) infusion once 
every two weeks. The dose was based on the patient’s actual body weight and only 
recalculated if there was a weight change of >10% from baseline. The initial dose was 
administered over 90 minutes. If no adverse reactions occurred after the initial dose, the 
second dose was administered over 60 minutes. If no adverse reactions occurred after the 
second dose, all subsequent doses were administered over 30 minutes. If infusion-related 
adverse reactions occurred at any time, subsequent doses of bevacizumab were administered 
over the shortest period that was well tolerated. Routine premedication was not required for 
the first dose of bevacizumab. If infusion reactions occurred, diphenhydramine, 
dexamethasone and an H1 blocker were administered as premedication. IV bevacizumab 
was administered before the oral dose of everolimus or placebo.
Everolimus or placebo was dispensed as tablets at the beginning of each treatment cycle 
(day 1, every 4 weeks). All dosages were prescribed and dispensed to the patient and all 
dose changes during the study were recorded. Everolimus or placebo was administered 
orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until 
progression of disease or unacceptable toxicity. Patients were instructed to take everolimus 
or placebo in the morning, at the same time each day. Everolimus or placebo was taken by 
the patient in a fasting state or with no more than a light fat-free meal. Dietary habits around 
the time of tablet intake were kept as consistent as possible throughout the study and if 
applicable, no attempt to replace the vomited dose.
Prior to each IV treatment, special attention was given to known bevacizumab effects: blood 
pressure, proteinuria, bleeding, cardiovascular events and bowel perforation. Type of blood 
pressure medications was administered at the discretion of the investigator.
For the oral everolimus or placebo, nausea and vomiting were managed at the investigator 
discretion with guidelines given for interacting medications. Diarrhea was managed with 
loperamide. Mild mucositis treated with conservative measures such as non-alcoholic and/or 
salt water (0.9%) mouth wash; more severe mucositis required topical analgesic and/or 
topical corticosteroid mouth treatments. Significant fasting hypercholesterolemia (>300 
mg/dL or 7.75 mmol/L) or hypertriglyceridemia (>300 mg/dL or >3.42 mmol/L) were 
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treated with a statin or appropriate lipid-lowering medication in addition to diet. Patients 
with diabetes were instructed to monitor glucose levels closely and may alter insulin and/or 
oral hypoglycemic therapy requirements. To avoid drug interactions, patients were instructed 
not to take any additional medications (including over-the-counter products) during the 
course of the study without prior consultation with the investigator. Concurrent 
administration of everolimus and strong or moderate CYP3A4 inhibitors, strong CYP3A4 
inducers and strong and moderate inhibitors of P-glycoprotein (PgP) were avoided.
Dose Modifications
Dose reductions were not allowed for bevacizumab. Interruption of bevacizumab was 
mandated for certain adverse events (grade 2 symptomatic hypertension, grade 3 
thromboembolic events or hypertension, >3.5gm proteinuria over 24 hours, grade 3 
hemorrhage) with intervention guidelines and parameters to restart. Bevacizumab was 
discontinued permanently for grade ≥2 arterial thromboembolic events or intracranial/
pulmonary hemorrhage; grade >3 AE, including allergic infusion reactions and wound 
complications; any grade ≥4 including symptomatic venous thromboembolic events, 
hypertension, and hemorrhage. Any grade of posterior reversible encephalopathy syndrome 
(PRES), wound dehiscence, perforation, fistula or nephrotic syndrome (or persistent 
proteinuria >3.5 gm) required discontinuation of bevacizumab. If bevacizumab was 
interrupted for toxicity, everolimus or placebo could continue. Patients were removed from 
the study if bevacizumab was not given for greater than 8 weeks. If everolimus or placebo 
was interrupted for any reason for >3 weeks, oral therapy was discontinued; however 
patients could continue on the study with bevacizumab alone.
Dose reductions were allowed with everolimus or placebo (initial dose 10mg; level 1 dose 
reduction at 5 mg daily; level 2 dose reduction at 5 mg every other day). Persistent (˃24 
hours) grade 3 non-hematologic toxicity in spite of optimal medical management required 
reduction of one dose level and delay in subsequent therapy for a maximum of three weeks 
until recovered to grade 1. Grade 2 (symptomatic) and grade 3 pneumonitis required 
corticosteroid administration. Everolimus or placebo was discontinued for any grade 4 AE, 
treatment hold for >3 weeks, or related adverse events requiring dose modification despite 
two previous dose reductions.
Study Endpoints
Tumor measurements using (computed tomography or magnetic resonance imaging) were 
made once during every other 4-week cycle according to RECIST 1.1 for the first six months 
and then every 3 cycles thereafter; and at any other time if clinically indicated based on 
symptoms or physical signs suggestive of progression of disease or rising serum CA-125 
tumor markers. For those with measurable disease, progression (PD) was defined as at least 
a 20% increase in the sum of the diameters of the target lesions, taking as reference the 
smallest sum on the study. In addition to the relative increase of at least 20%, the sum must 
also demonstrate an absolute increase of at least 5mm. The appearance of one or more new 
lesions or unequivocal progression of non-target lesions was also considered PD. Partial 
response was defined as at least a 30% decrease in the sum of the diameters of target lesions 
from the baseline sum. Complete response was defined as the disappearance of all target and 
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non-target lesions and no new lesions. Stable disease was any condition not meeting the 
above criteria. Responses required confirmation on repeat imaging at greater than or equal to 
4 weeks from initial documentation.
For those with detectable but non-measurable disease, assessment was based on CA-125, 
malignant fluid (i.e. ascites or pleural effusion), and/or evaluation of indeterminate solid or 
cystic abnormalities. CA-125 responses, regardless of measurable status, were assessed with 
Rustin criteria. 27 Initial values within two weeks of starting therapy had to be 2x ULN to be 
considered evaluable. At least a 50% reduction in CA-125 levels from the baseline value was 
maintained for at least 28 days represented a partial response. A full response was defined as 
normalization (less than ULN) of CA-125 levels that maintained normal for at least 28 days. 
The date of progression by CA-125 level was determined by values ˃ 2x maximum (ULN, 
nadir) that was confirmed at least eight days later. If the date of progression was within eight 
weeks, PD was entered. If patients had evaluations more than eight weeks from study entry 
without PD, then their response was at least stable disease. Patients were evaluated by using 
best overall response while receiving study therapy.
Statistical Design
The primary objective of this study was to estimate the PFS hazard ratio (HR) of the 
combination of oral everolimus and bevacizumab to oral placebo and bevacizumab. The 
study was powered to detect a true 37.5% reduction in the hazard ratio of PFS by using the 
Cox proportional hazards model. The target enrollment was 150 patients (75 per arm) with 
123 events to achieve 90% power with a 10% level of significance when conducted with an 
interim analysis (at approximately the 62nd event) using the method provided by Weiand et 
al. that rejected the study drug when the HR>1.24 There was no suspension of study accrual 
during the interim analysis. The final analysis involving efficacy used the intent to treat 
principle and occurred at approximately the 123rd event (taken from both arms).25 
Secondary objectives included 1) to estimate and compare the nature and degree of toxicity 
of oral everolimus (or placebo) plus bevacizumab, 2) to characterize and compare PFS and 
OS in patients with measurable disease (RECIST criteria) and patients with detectable (non-
measurable) disease, 3) to estimate the proportion of patients with measurable disease who 
have objective tumor responses by treatment, and 4) to provide descriptive information about 
CA-125 responses by regimen and where possible by objective tumor responses. Estimates 
of the differences between measurable versus non-measurable disease status on PFS and OS 
was proposed with plots of survival curves, estimates of quartiles, and hazard ratios where 
feasible. For everolimus or placebo randomization, patients were stratified according to their 
platinum-free interval (≤182 days versus >182 days), disease status (measurable versus 
detectable), and prior use of bevacizumab/aflibercept therapy (no use versus prior use).
RESULTS
The study opened on 12/28/2010, was suspended on 3/9/2011 due to problems with 
unblinding, reopened on 7/18/2011 and was closed to patient entry on 8/14/2012 after the 
enrollment of 150 patients. During the first 3-month suspension period, there were only 2 
patients enrolled. However, a second unblinding occurred later where at least 52 patients in 
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total were potentially unblinded. The group quickly obtained another distributor of the 
regimens to avoid further errors. The only ordinary indication for un-blinding was a serious 
adverse event in which it is determined by the Study Chair that un-blinding would improve 
patient safety.
The primary outcome data was frozen on 8/26/2013 for the final analysis. All randomly 
assigned patients were included in the analysis of efficacy (intention to treat). Five patients 
were never treated (2 in the everolimus experimental arm and 3 in the bevacizumab only 
arm) and thus, 145 patients were evaluable for toxicity (Figure 1). Patient demographic 
characteristics are outlined in Table 1 and the two treatment arms were well balanced for age 
(median 63: range 28–92), PS (0: 73%, 1–2: 27%), prior regimens (1: 37%, 2: 47%, 3: 
16%), prior BV (11%), PFI (<6mos: 65%) and measurable disease (81%).
The interim analysis was triggered after 62 PFS events and the final analysis after 127 PFS 
events. Adding everolimus to bevacizumab did not significantly prolong PFS compared to 
bevacizumab alone (median PFS 4.5 months for bevacizumab and 5.9 months for 
bevacizumab plus everolimus; HR, 0.95; with 95% CI, 0.66 to 1.37; one-sided P=0.39; 
Figure 2A). At the time of this data analysis, 73 had died and median follow-up on the 
bevacizumab alone arm was 15 months and 15.7 months on the everolimus arm. There was 
no significant difference in OS (median OS 17.3 months for bevacizumab and 16.6 months 
for bevacizumab plus everolimus; HR, 1.16; with 95% CI, 0.72 to 1.87; two-sided P=0.55; 
Figure 2B).
Among patients with measurable disease, the objective response was about 2x higher with 
bevacizumab plus everolimus (22% vs 12%; relative probability of responding was 1.84, 
95% CI 0.80 to 4.24). Among patients with CA-125 evaluable disease, the CA125 response 
was about 2x higher response with bevacizumab plus everolimus (27% vs 15%). The odds 
ratio for radiographic response (experimental to reference) was 2.08 (95% Exact CI 0.71 to 
6.60), so although the data favored the experimental regimen through point estimates, the 
interval estimates were not suggestive of the experimental regimen being superior. The 
frequency of study removal due to toxicity or patient refusing further treatment was high 
with the combination regimen (41%) compared to bevacizumab alone (17%). (Table 2) 
There was no significant association between treatment related death and study regimen. The 
two patients (one on each treatment arm) who had grade 5 adverse events related to study 
treatment had a thromboembolism and a hematoma. Sixty-five patients died from 
progressive disease. Treatment related adverse events are listed in Table 3. The addition of 
everolimus to bevacizumab was associated with higher toxicities including neutropenia, 
anemia, thrombocytopenia, nausea, oral mucositis, fatigue, metabolic abnormalities, dyspnea 
and rash. There were three events of a grade 3–4 gastrointestinal perforation (2%).
DISCUSSION
Bevacizumab has clinical activity as both a single agent and in combination with cytotoxic 
chemtherapy. Based on the AURELIA trial (AURELIA: A Study of Avastin (bevacizumab) 
Added to Chemotherapy in Patients with Platinum-resistant Ovarian Cancer), bevacizumab 
first received approval in the United States in November 2014. By combining chemotherapy 
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– weekly paclitaxel, liposomal doxorubicin or topotecan – with bevacizumab, the median 
PFS was improved by 3.3 months (range, 3.4 months to 6.7 months; HR, 0.48; 95% CI, 0.38 
to 0.6) and patients reported improvement in disease-realated symptoms and quality of life.
7–8
 However, chemotherapy-related toxicties was significant. The GOG created a 
randomized phase II trial platform (GOG-186 series) to compare non-cytotoxic 
combinations to single agent targeted agents with the objective to improve the therapeutic 
ratio of emerging agents in ovarian cancer. A recent study on this GOG-186 series showed 
promising response and tolerability when combinging two antivascular agents (bevacizuamb 
plus flubretulin) compared to bevacizumab alone.26
Unfortunately, as demonstarted in our trial, everolimus when combined with bevacizumab 
was an active combination but did not reach the goal of improving PFS or tolerability. This 
randomized phase II trial comparing bevacizumab alone (plus oral placebo) to bevacizumab 
plus everolimus did not significantly prolong PFS compared to bevacizumab alone (median 
PFS 4.5 months for bevacizumab and 5.9 months for bevacizumab plus everolimus; HR, 
0.95; with 95% CI, 0.66 to 1.37; one-sided P=0.39). However, the regimen was active 
particularly in women with measurable disease; the objective response (complete or partial 
response) was two-fold higher with bevacizumab plus everolimus (22% vs 12%). The side 
effects were considerable and study removal due to toxicity or patient refusing further 
treatment was high with the combination regimen (41%) compared to bevacizumab alone 
(17%).
The advantage of this trial was its multicenter and randomized design. The inclusion of a 
placebo in the design was intended to reduce bias. However, there was an accidental 
unblinding at several sites due to a distributor error (exposed label of the un-blinding to 
multiple site pharmacies) and therefore, the power of the placebo inclusion was lost in the 
final analysis. It is unlikely, however, this had a significant factor to the final conclusions of 
the study – as most patients on everolimus could easily be determined by the high reports of 
toxicities compared to the placebo group.
In conclusion, we cannot recommend further exploration of the combination of everolimus 
and bevacizumab in women with recurrent ovarian cancer.
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RESEARCH HIGHLIGHTS
• Bevacizumab monotherapy is active therapy for recurrent ovarian cancer, but 
resistance is common
• BV+EV combination had a higher measurable response (22% vs 12%) 
compared to BV alone
• BV+EV combination had higher toxicity and study removal (29% vs 12%) 
compared to BV alone
• BV+EV combination did not improve progression free or overall survival
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Figure 1: 
Study enrollment diagram
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Figure 2A: 
Progression-free survival (PFS) analysis by intent to treat.
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Figure 2B: 
Overall survival (OS) analysis by intent to treat.
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Table 1:
Demographics and Baseline Characteristics
Bevacizumab alone Bevacizumab + Everolimus TOTAL
No % No %
Characteristics
Age Groups, years
 20–29 1 1.33 0 0 1
 30–39 1 1.33 1 1.33 2
 40–49 9 12.00 8 10.67 17
 50–59 16 21.33 21 28.00 37
 60–69 33 44.00 28 37.33 61
 70–79 12 16.00 13 17.33 25
 >= 80 3 4.00 4 5.33 7
Ethnicity
  Hispanic 1 1.33 2 2.67 3
  Non-Hispanic 65 86.67 69 92.00 134
  Unknown 9 12.00 4 5.33 13
Race
  Asian 2 2.67 3 4.00 5
  African American 6 8.00 3 4.00 9
  White 65 86.67 69 92.00 134
  Unknown 2 2.67 0 0 2
Performance Status
  0 58 77.33 52 69.33 110
  1 17 24.00 21 28.00 38
  2 0 2.67 2 2.67 2
Cell Type
 Endometrioid 4 5.33 3 4.00 7
 Serous 59 78.67 54 72.00 113
 Clear cell 7 9.33 5 6.67 12
 Mixed epithelial 3 4.00 4 5.33 7
 Undifferentiated 0 0.00 2 2.67 2
 Adenocarcinoma, NOS 2 2.67 7 9.33 2
No. of prior regimens
 1 23 32.00 32 42.67 55
 2 39 54.67 31 41.33 70
 3 13 21.33 12 16.00 25
Prior Radiation
 No 74 98.67 73 97.33 147
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Bevacizumab alone Bevacizumab + Everolimus TOTAL
No % No %
Characteristics
 Yes 1 1.33 2 2.67 3
Prior Immunotherapy
 No 73 97.33 74 98.67 147
 Yes 2 2.67 1 1.33 3
Prior Surgery
 No 5 6.67 1 1.33 6
 Yes 70 93.33 74 98.67 144
Prior bevacizumab
 No 66 88.00 68 90.67 134
 Yes 9 12.00 7 9.33 16
Measurable disease
 No 12 16.00 17 22.67 29
 Yes 63 84.00 58 77.33 121
Platinum interval
 Platinum resistant  (<6mo PFI) 47 62.67 51 68.00 98
 Platinum sensitive (6  < PFI <12mo) 28 37.33 54 32.00 52
TOTAL (n=150) 75 100% 75 100% 150
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Table 2:
Response to Therapy and Patient Outcomes
Bevacizumab alone Bevacizumab + Everolimus
Characteristics No. % No. % Total
Response
 Complete response  0 0 1 1 1
 Partial response  7 9 13 17 20
 Stable disease 30 40 32 43 62
 Progressive disease 16 21 11 15 27
 Indeterminate  5 7 6 8 11
 Non-measurable 17 23 12 16 29
Alive/cause of death
 Dead from disease 31 41 34 45 65 (43%)
 Dead, drug related  0 0 1 1 1 (1%)
 Dead, drug-related and disease  1 1 1 1 2 (1%)
 Dead, undetermined cause  3 3 2 3 5 (3%)
 Alive 40 53 37 49 77(51%)
Reason off study
 Disease progression 49 65 37 49 86 (57%)
 Toxicity per protocol  9 12 22 29 31 (21%)
 Refused further treatment  4 5 9 12 13 (9%)
 Other disease  1 1 2 3 3 (2%)
 Other, unknown, or on study 12 16 5 7 17 (12%)
Note: The relative probability of response on the everolimus + bevacizumab arm compared with the bevacizumab alone arm (among patients with 
measurable disease) was 1.84 (95% CI 0.80–4.24). The odds ratio was 2.08 (95% CI, 0.71–6.60).
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Table 3:
Treatment Adverse Events (no. of events)
Bevacizumab alone (n=72) Bevacizumab + Everolimus (n=73)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Blood/Lymphatics
  Neutropenia1 5 1 0 0 0 11 15 5 0 0
  Anemia1 18 5 0 0 0 24 22 1 0 0
  Thrombocytopenia1 6 2 0 0 0 28 10 1 0 0
Cardiac 1 0 1 0 0 5 1 0 1 0
Ear/labyrinth 2 0 0 0 0 2 20 0 0 0
Gastrointestinal
  Nausea1 19 3 4 0 0 13 12 6 0 0
  Vomiting 5 4 2 0 0 13 7 5 0 0
  Other GI1,2 34 8 1 0 0 23 22 13 1 0
General/ 43 9 1 0 0 34 20 7 0 0
administrative site1
Hepatobiliary 0 0 0 0 0 0 2 0 0 0
Immune system 0 0 0 0 0 0 2 0 0 0
Infections 1 6 2 0 0 2 7 6 1 0
Metabolism/nutrition1,2 18 4 4 1 0 15 14 13 1 0
Musculoskeletal/ connective tissue 24 6 1 0 0 12 8 4 0 0
Nervous system 21 6 2 0 0 28 9 3 0 0
 Peripheral neuropathy 10 1 0 0 0 12 1 1 0 0
Other investigations 18 4 2 0 0 18 20 2 0 0
Psychiatric 5 1 0 0 0 8 4 0 0 0
Renal/urinary 7 0 2 0 0 8 5 1 0 0
Respiratory/thoracic1 26 3 0 0 0 26 12 4 1 0
Skin/subcutaneous1 16 2 0 0 0 24 10 2 0 0
Vascular disorders 7 11 10 2 1 4 7 12 1 1
1–
Toxicities are significantly associated with treatment at the 5% level when classified as mild (Grade <=1), moderate (grade =2) and severe (Grade 
>=3) (highlighted as a light shadow in table)
2–
Toxicities are significantly associated with treatment at the 5% level when classified as mild to moderate and severe (grade 3–5 non-hematologic 
and grade 4–5 hematologic events) (highlighted as a dark shadow in table)
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